<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: Additional ", fill: "#4997d0"},
{source: "2: Additional ", target: "2: uncertainties", fill: "#4997d0"},
{source: "2: uncertainties", target: "2: presently known", fill: "#4997d0"},
{source: "2: presently known", target: "2: immaterial may also impair", fill: "#4997d0"},
{source: "2: immaterial may also impair", target: "2: operations", fill: "#4997d0"},
{source: "2: Additional ", target: "3: risks actually", fill: "#3f00ff"},
{source: "3: risks actually", target: "3: financial condition", fill: "#3f00ff"},
{source: "3: financial condition", target: "3: materially adversely affected", fill: "#3f00ff"},
{source: "3: risks actually", target: "9: Approximately ", fill: "#0067a5"},
{source: "9: Approximately ", target: "9: December ", fill: "#0067a5"},
{source: "9: December ", target: "9: derived from", fill: "#0067a5"},
{source: "9: derived from", target: "9: Heart Laser Systems", fill: "#0067a5"},
{source: "9: Approximately ", target: "10: product line", fill: "#f88379"},
{source: "10: product line", target: "10: materially impacted by", fill: "#f88379"},
{source: "10: materially impacted by", target: "10: Heart Laser Systems", fill: "#f88379"},
{source: "10: product line", target: "16: must effectively", fill: "#ee82ee"},
{source: "16: must effectively", target: "16: significant", fill: "#ee82ee"},
{source: "16: significant", target: "16: competition", fill: "#ee82ee"},
{source: "16: competition", target: "16: competitive", fill: "#ee82ee"},
{source: "16: competitive", target: "16: technologies", fill: "#ee82ee"},
{source: "16: must effectively", target: "31: raise additional capital upon", fill: "#ace5ee"},
{source: "31: raise additional capital upon", target: "31: financial condition", fill: "#ace5ee"},
{source: "31: financial condition", target: "31: operations could", fill: "#ace5ee"},
{source: "31: operations could", target: "31: materially", fill: "#ace5ee"},
{source: "31: materially", target: "31: adversely affected", fill: "#ace5ee"},
{source: "31: raise additional capital upon", target: "36: demonstrate", fill: "#bd33a4"},
{source: "36: demonstrate", target: "36: cardiologists", fill: "#bd33a4"},
{source: "36: cardiologists", target: "36: arrhythmias", fill: "#bd33a4"},
{source: "36: arrhythmias", target: "36: effective", fill: "#bd33a4"},
{source: "36: effective", target: "36: relatively", fill: "#bd33a4"},
{source: "36: relatively", target: "36: thirdparty", fill: "#bd33a4"},
{source: "36: thirdparty", target: "36: procedures relieve angina", fill: "#bd33a4"},
{source: "36: procedures relieve angina", target: "36: surgical tissue ablation cures", fill: "#bd33a4"},
{source: "36: surgical tissue ablation cures", target: "36: cardiac arrhythmias", fill: "#bd33a4"},
{source: "36: cardiac arrhythmias", target: "36: heart surgeons trained", fill: "#bd33a4"},
{source: "36: heart surgeons trained", target: "36: procedures using", fill: "#bd33a4"},
{source: "36: procedures using", target: "36: thirdparty", fill: "#bd33a4"},
{source: "36: thirdparty", target: "36: reimbursement", fill: "#bd33a4"},
{source: "36: reimbursement", target: "36: for the TMR ", fill: "#bd33a4"},
{source: "36: demonstrate", target: "55: regulations", fill: "#90ee90"},
{source: "55: regulations", target: "55: regulatory", fill: "#90ee90"},
{source: "55: regulatory", target: "55: requirements", fill: "#90ee90"},
{source: "55: requirements", target: "55: govern among", fill: "#90ee90"},
{source: "55: govern among", target: "55: product design", fill: "#90ee90"},
{source: "55: product design", target: "55: development", fill: "#90ee90"},
{source: "55: development", target: "55: product testing", fill: "#90ee90"},
{source: "55: product testing", target: "55: product labeling", fill: "#90ee90"},
{source: "55: product labeling", target: "55: product storage", fill: "#90ee90"},
{source: "55: product storage", target: "55: premarket clearance", fill: "#90ee90"},
{source: "55: premarket clearance", target: "55: advertising", fill: "#90ee90"},
{source: "55: advertising", target: "55: product sales", fill: "#90ee90"},
{source: "55: product sales", target: "55: distribution", fill: "#90ee90"},
{source: "55: regulations", target: "START_HERE", fill: "#90ee90"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Laser_rangefinder">Laser rangefinder</a></td>
      <td>A laser rangefinder, also known as a laser telemeter, is a rangefinder that uses a laser beam to determine the distance to an object. The most common form of laser rangefinder operates on the time of flight principle by sending a laser pulse in a narrow beam towards the object and measuring the time taken by the pulse to be reflected off the target and returned to the sender.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Directed-energy_weapon">Directed-energy weapon</a></td>
      <td>A directed-energy weapon (DEW) is a ranged weapon that damages its target with highly focused energy, including lasers, microwaves, particle beams, and sound beams. Potential applications of this technology include weapons that target personnel, missiles, vehicles, and optical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Time-of-flight_camera">Time-of-flight camera</a></td>
      <td>A time-of-flight camera (ToF camera) is a range imaging camera system employing time-of-flight techniques to resolve distance between the camera and the subject for each point of the image, by measuring the round trip time of an artificial light signal provided by a laser or an LED. Laser-based time-of-flight cameras are part of a broader class of scannerless LIDAR, in which the entire scene is captured with each laser pulse, as opposed to point-by-point with a laser beam such as in scanning LIDAR systems.\nTime-of-flight camera products for civil applications began to emerge around 2000, as the semiconductor processes allowed the production of components fast enough for such devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ablation">Ablation</a></td>
      <td>Ablation (Latin: ablatio — removal) is removal or destruction of something from an object by vaporization, chipping,  erosive processes or by other means. Examples of ablative materials are described below, and include spacecraft material for ascent and atmospheric reentry, ice and snow in glaciology, biological tissues in medicine and passive fire protection materials.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Artificial_cardiac_pacemaker">Artificial cardiac pacemaker</a></td>
      <td>A cardiac pacemaker (or artificial pacemaker, so as not to be confused with the natural pacemaker of the heart) is a medical device that generates electrical impulses delivered by electrodes to cause the heart muscle chambers (the upper, or atria and/or the lower, or ventricles) to contract and therefore pump blood. By doing so, this device replaces and/or regulates the function of the electrical conduction system of the heart.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Composite_material">Composite material</a></td>
      <td>A composite material (also called a composition material or shortened to composite, which is the common name) is a material which is produced from two or more constituent materials. These constituent materials have notably dissimilar chemical or physical properties and are merged to create a material with properties unlike the individual elements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Materials_science">Materials science</a></td>
      <td>The interdisciplinary field of materials science covers the design and discovery of new materials, particularly solids. The field is also commonly termed materials science and engineering emphasizing engineering aspects of building useful items, and materials physics, which emphasizes the use of physics to describe material properties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Building_material">Building material</a></td>
      <td>Building material is material used for construction. Many naturally occurring substances, such as clay, rocks, sand, wood, and even twigs and leaves, have been used to construct buildings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Time_and_materials">Time and materials</a></td>
      <td>Time and materials (T&amp;M) is a standard phrase in a contract for construction, product development or any other piece of work in which the employer agrees to pay the contractor based upon the time spent  by the contractor's employees and subcontractors employees to perform the work, and for materials used in the construction (plus the contractor's mark up on the materials used), no matter how much work is required to complete construction. Time and materials is generally used in projects in which it is not possible to accurately estimate the size of the project, or when it is expected that the project requirements would most likely change.This is opposed to a fixed-price contract in which the owner agrees to pay the contractor a lump sum for fulfillment of the contract no matter what the contractors pay their employees, sub-contractors and suppliers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lime_(material)">Lime (material)</a></td>
      <td>Lime is a calcium-containing inorganic mineral composed primarily of  oxides, and hydroxide, usually calcium oxide and/or calcium hydroxide. It is also the name for calcium oxide which occurs as a product of coal-seam fires and in altered limestone xenoliths in volcanic ejecta.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Strength_of_materials">Strength of materials</a></td>
      <td>The field of strength of materials, also called mechanics of materials, typically refers to various methods of calculating the stresses and strains in structural members, such as beams, columns, and shafts. The methods employed to predict the response of a structure under loading and its susceptibility to various failure modes takes into account the properties of the materials such as its yield strength, ultimate strength, Young's modulus, and Poisson's ratio.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fee_Reimbursement_Scheme_(Andhra_Pradesh)">Fee Reimbursement Scheme (Andhra Pradesh)</a></td>
      <td>The Fee Reimbursement Scheme (also known as the Post-matric Scholarship Scheme) is a student education sponsorship programme of the Government of Andhra Pradesh. It supports students from lower economic strata in the state.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirement">Requirement</a></td>
      <td>In product development and process optimization, a requirement is a singular documented physical or functional need that a particular design, product or process aims to satisfy. It is commonly used in a formal sense in engineering design, including for example in systems engineering, software engineering, or enterprise engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-functional_requirement">Non-functional requirement</a></td>
      <td>In systems engineering and requirements engineering, a non-functional requirement (NFR) is a requirement that specifies criteria that can be used to judge the operation of a system, rather than specific behaviours. They are contrasted with functional requirements that define specific behavior or functions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Visa_requirements_for_United_States_citizens">Visa requirements for United States citizens</a></td>
      <td>As of 25 February 2022, Holders of a United States passport could travel to 186 countries and territories without a travel visa, or with a visa on arrival. The United States passport currently ranks 6th in terms of travel freedom (tied with the passports of Czech Republic, Greece, Malta, Norway, and the UK) according to the Henley Passport Index.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_engineering">Requirements engineering</a></td>
      <td>Requirements engineering (RE) is the process of defining, documenting, and maintaining requirements in the engineering design process. It is a common role in systems engineering and software engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_analysis">Requirements analysis</a></td>
      <td>In systems engineering and software engineering, requirements analysis focuses on the tasks that determine the needs or conditions to meet the new or altered product or project, taking account of the possibly conflicting requirements of the various stakeholders, analyzing, documenting, validating and managing software or system requirements.Requirements analysis is critical to the success or failure of a systems or software project. The requirements should be documented, actionable, measurable, testable, traceable, related to identified business needs or opportunities, and defined to a level of detail sufficient for system design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Age_of_candidacy">Age of candidacy</a></td>
      <td>Age of candidacy is the minimum age at which a person can legally hold certain elected government offices. In many cases, it also determines the age at which a person may be eligible to stand for an election or be granted ballot access.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_requirements_document">Market requirements document</a></td>
      <td>A market requirements document (MRD) in project management and systems engineering, is a document that expresses the customer's wants and needs for the product or service.\nIt is typically written as a part of product marketing or product management.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Visa_requirements_for_British_citizens">Visa requirements for British citizens</a></td>
      <td>Visa requirements for British citizens are administrative entry restrictions by the authorities of other states placed on citizens of the United Kingdom. As of 30 April 2022, British citizens had visa-free or visa on arrival access to 187 countries and territories, ranking their passport 5th in terms of travel freedom (tied with France, Ireland and Portugal) according to the Henley Passport Index.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>PLC SYSTEMS INC      Item 1A Risk Factors       The risks and <font color="blue"><font color="blue">uncertainties</font> described</font> below are not the only risks we face</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font> not <font color="blue">presently known</font> to us or currently     deemed <font color="blue">immaterial may also impair</font> our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of the     following  <font color="blue">risks actually</font> occur, our <font color="blue">financial condition</font> and operating     results could be <font color="blue"><font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affected</font></font></td>
    </tr>
    <tr>
      <td>12     ______________________________________________________________________       We expect to incur <font color="blue">significant</font> operating losses in the near future       We incurred a net loss of dlra1cmam268cmam000 for the year ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>We expect to continue to <font color="blue">incur net losses</font> for at least the next 12-24 months     as  we  increase  our  spending  primarily in the area of research and     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Moreover, as we continue to pursue our business strategy of     acquiring or developing <font color="blue">new medical devices</font> to <font color="blue">address cardiac</font> and vascular     related markets, we <font color="blue">may continue</font> to <font color="blue">incur expenses</font> that exceed the revenues     we generate</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot provide</font> any assurance that we will be successful with     our business strategy, that any new products under <font color="blue">development</font> will be     successful or that we <font color="blue">will ever return</font> to <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our company is <font color="blue">currently <font color="blue">dependent</font> on one principal <font color="blue">product line</font></font> to generate     revenues       We currently sell one principal <font color="blue">product line</font>, which consists of two patented     high-powered carbon dioxide lasers and related TMR <font color="blue">disposable kits known as</font>     the  Heart  Laser Systems, <font color="blue">which account</font> for the majority of our total     revenue</td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>89prca and 90prca, of our revenues in the years ended     <font color="blue">December </font>31, 2005 and <font color="blue">December </font>31, 2004, <font color="blue">respectively</font>, were <font color="blue">derived from</font> the     sales and service of our <font color="blue">Heart Laser Systems</font></td>
    </tr>
    <tr>
      <td>This absence of a diversified     <font color="blue">product line</font> means that we are directly and <font color="blue"><font color="blue">materially</font> impacted by</font> changes     in the market for <font color="blue">Heart Laser Systems</font></td>
    </tr>
    <tr>
      <td>Our company is <font color="blue"><font color="blue">dependent</font> on one principal customer</font>       <font color="blue">Pursuant  </font>to the terms of our TMR <font color="blue"><font color="blue">distribution</font> agreement with</font> Edwards,     Edwards is our <font color="blue">exclusive <font color="blue">distributor</font></font> for our HL2 TMR laser and TMR kits in     the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In addition, we are the <font color="blue">exclusive <font color="blue">manufacturer</font></font> of the     <font color="blue">current version</font> of <font color="blue">the Optiwave </font>980 laser console for Edwards</td>
    </tr>
    <tr>
      <td>As a result     of these exclusive <font color="blue">arrangements</font>, Edwards accounted for 89prca and 88prca of our     total revenues in the years ended <font color="blue">December </font>31, 2005 and <font color="blue">December </font>31, 2004,     <font color="blue">respectively</font>, and we expect Edwards to account for the <font color="blue"><font color="blue">significant</font> majority</font>     of our revenue in the near future</td>
    </tr>
    <tr>
      <td>If our <font color="blue">relationship with</font> Edwards does not     progress as anticipated, or if Edwards’ sales and <font color="blue">marketing strategies fail</font>     to <font color="blue">generate sales</font> of our products in the future, our <font color="blue">revenue will decrease</font>     <font color="blue"><font color="blue">significant</font>ly</font>  and  our  business,  <font color="blue">financial condition</font> and results of     <font color="blue">operations</font> will be <font color="blue">seriously harmed</font></td>
    </tr>
    <tr>
      <td>Our ability to realize <font color="blue">future revenues from</font> <font color="blue">the Optiwave </font>980 is <font color="blue">dependent</font>     upon Edwards <font color="blue">successfully launching</font> this new product into an <font color="blue">existing market</font>     with a <font color="blue">new sales team</font>       <font color="blue">Edwards  </font>has  <font color="blue">only recently</font> completed its <font color="blue">marketing <font color="blue">evaluation</font>s</font> of the     Optiwave 980 System and, as a result, has a limited amount of experience     selling this new product into the US market</td>
    </tr>
    <tr>
      <td>Edwards <font color="blue">must <font color="blue">effective</font>ly</font>     train  a  new  sales  team to market <font color="blue">the Optiwave </font>980 System and faces     <font color="blue">significant</font> <font color="blue">competition</font> from several other companies that have been selling     <font color="blue">competitive</font> non-laser based <font color="blue">technologies</font> for several years</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font>     you that Edwards will successfully commercialize <font color="blue">the Optiwave </font>980 System or     that we will ever receive any or all of the <font color="blue">royalty revenue</font> we negotiated to     receive from the sale of <font color="blue">disposable products under</font> our <font color="blue">royalty agreement</font>     with Edwards</td>
    </tr>
    <tr>
      <td>Our company is <font color="blue">dependent</font> on certain suppliers       Some of the <font color="blue">components</font> for our <font color="blue">Heart Laser Systems</font>, <font color="blue">most notably</font> the power     supply and <font color="blue">certain optics</font> and <font color="blue">fabricated parts</font> for the HL2, and certain     <font color="blue">components</font>  for  the  Optiwave 980 System, are <font color="blue">only available from one</font>     supplier, and we have no assurance that we will be able to source any of our     sole-sourced <font color="blue">components</font> from <font color="blue">additional</font> suppliers</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent</font> upon our     <font color="blue">sole suppliers</font> to perform their <font color="blue">obligations</font> in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>In the past,     we have experienced delays in product delivery from our <font color="blue">sole suppliers</font> and,     because we do not have an <font color="blue">alternative</font> supplier to produce these products for     us, we have little leverage to enforce timely delivery</td>
    </tr>
    <tr>
      <td>Any delay in product     delivery or other <font color="blue">interruption</font> in <font color="blue">supply from</font> these <font color="blue">suppliers could prevent</font>     <font color="blue">us from meeting</font> our <font color="blue">commercial demands</font> for our products, which could       13     ______________________________________________________________________       have a material adverse effect on our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Furthermore, we do not require <font color="blue">significant</font> quantities     of any <font color="blue">components</font> because we produce a limited number of our <font color="blue">products each</font>     year</td>
    </tr>
    <tr>
      <td>Therefore,  it  may  be  <font color="blue">difficult</font>  for us to continue our     <font color="blue">relationships with</font> our <font color="blue">current suppliers</font> or establish <font color="blue">relationships with</font>     <font color="blue"><font color="blue">additional</font> suppliers on commercially reasonable terms</font>, if at all, and such     <font color="blue">difficult</font>ies  <font color="blue">may seriously harm</font> our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent</font> upon our <font color="blue">key personnel</font> and will need to hire <font color="blue">additional</font> key     personnel in the near future       Our ability to operate our business <font color="blue">successfully depends</font> in <font color="blue">significant</font> part     upon the retention and motivation of certain key technical, <font color="blue">regulatory</font>,     production and <font color="blue">managerial personnel</font> and <font color="blue">consultants</font> and our <font color="blue">ongoing ability</font>     to  hire  and  retain  <font color="blue">additional</font>  <font color="blue">qualified personnel</font> in these areas</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for such personnel is intense, <font color="blue">particularly</font> in the Greater     Boston area</td>
    </tr>
    <tr>
      <td>We cannot be certain that we will be able to <font color="blue">attract such</font>     personnel and the loss of any of our <font color="blue">current key employees</font> or <font color="blue">consultants</font>     could have a <font color="blue">significant</font> adverse <font color="blue">impact on</font> our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">company may</font> be unable to raise needed funds       As  of <font color="blue">December </font>31, 2005, we had cash, cash equivalents and short-term     investments totaling dlra9cmam460cmam000</td>
    </tr>
    <tr>
      <td>Based on our current operating plan, we     anticipate that our <font color="blue">existing capital resources should</font> be sufficient to meet     our working <font color="blue">capital <font color="blue">requirements</font></font> for at least the next 12 months</td>
    </tr>
    <tr>
      <td>However,     if our business does not progress in <font color="blue">accordance with</font> our current business     plan, we may need to raise <font color="blue">additional</font> funds in the future</td>
    </tr>
    <tr>
      <td>We may not be     able to raise <font color="blue">additional</font> capital upon satisfactory terms, or at all, and our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font> could be <font color="blue">materially</font>     and <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>To the extent that we raise <font color="blue">additional</font> capital by     issuing  equity  or  convertible securities, ownership dilution to our     <font color="blue">shareholders</font> will result</td>
    </tr>
    <tr>
      <td>To the extent that we raise <font color="blue">additional</font> capital     through the incurrence of debt, our <font color="blue">activities</font> may be restricted by the     repayment <font color="blue">obligations</font> and other <font color="blue">restrictive covenants</font> related to the debt</td>
    </tr>
    <tr>
      <td>In order to <font color="blue">compete <font color="blue">effective</font>ly</font>, our current and <font color="blue">future products</font> need to     <font color="blue">gain commercial <font color="blue">acceptance</font></font>       TMR and surgical ablation for cardiac <font color="blue">arrhythmias</font> are still both novel     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Our current and planned <font color="blue">future products</font> may never achieve     <font color="blue"><font color="blue">widespread commercial</font> <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>To be successful, we and Edwards need to:       ·        <font color="blue">demonstrate</font> to the medical community in general, and to heart     surgeons and <font color="blue">cardiologists</font> in particular, that TMR and surgical tissue     ablation  for  cardiac  <font color="blue">arrhythmias</font> are procedures that are <font color="blue">effective</font>,     <font color="blue">relatively</font> safe and cost <font color="blue">effective</font>;       ·       support third-party efforts to document the medical processes by     which TMR <font color="blue">procedures relieve angina</font> and <font color="blue">surgical tissue ablation cures</font>     cardiac <font color="blue">arrhythmias</font>;       ·       have more <font color="blue"><font color="blue">heart surgeons</font> trained</font> to perform TMR <font color="blue">procedures using</font> the     Heart  Laser Systems and surgical tissue ablation <font color="blue">procedures using</font> the     Optiwave 980 System; and       ·       maintain and expand third-party <font color="blue">reimbursement</font> <font color="blue">for the TMR </font>procedure</td>
    </tr>
    <tr>
      <td>To date, only a limited number of <font color="blue">heart surgeons</font> have <font color="blue">been trained</font> in the     use  of  TMR using the <font color="blue">Heart Laser Systems</font> and cardiac tissue ablation     <font color="blue">procedures using</font> <font color="blue">the Optiwave </font>980 System</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent</font> on Edwards to     expand related marketing and training efforts <font color="blue">in the US </font>for the use of our     products</td>
    </tr>
    <tr>
      <td>The  Heart  Laser  Systems have not yet received <font color="blue">widespread commercial</font>     <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>We believe that <font color="blue">concerns over</font> the lack of a <font color="blue">consensus</font> view on     the reason or reasons why a TMR procedure relieves angina       14     ______________________________________________________________________       in patients who undergo the procedure has limited demand for and use of the     <font color="blue">Heart Laser Systems</font></td>
    </tr>
    <tr>
      <td>Until there is <font color="blue">consensus</font>, if ever, of the medical     <font color="blue">processes by which</font> TMR <font color="blue">procedures relieve angina</font>, we believe some hospitals     may delay the <font color="blue">implementation</font> of a TMR program</td>
    </tr>
    <tr>
      <td>If we are unable to achieve <font color="blue"><font color="blue">widespread commercial</font> <font color="blue">acceptance</font></font> of the Heart     Laser Systems or <font color="blue">the Optiwave </font>980 System, our business, <font color="blue">financial condition</font>     and results of <font color="blue">operations</font> will be <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Our  primary <font color="blue">competitor</font> in TMR may obtain FDA approval to market a new     device, the impact of which is <font color="blue">uncertain on</font> the <font color="blue">future adoption rate</font> of TMR       Our primary TMR <font color="blue">competitor</font>, CardioGenesis, is attempting to obtain FDA     approval to market their “<font color="blue">percutaneous</font>” method of performing myocardial     revascularization, <font color="blue">previously</font> known as PMR, and recently rebranded as PMC     (<font color="blue">percutaneous</font> myocardial channeling), which would provide a <font color="blue">less invasive</font>     method of creating channels in the heart</td>
    </tr>
    <tr>
      <td>If PMC can be shown to be safe and     <font color="blue">effective</font> and is <font color="blue">approved by</font> the FDA, it <font color="blue">would eliminate</font> the need in certain     patients to make an incision in the chest, reducing costs and speeding     recovery</td>
    </tr>
    <tr>
      <td>It is unclear what impact, if any, an approval of a PMC device     would  have  on the <font color="blue">future adoption rate</font> for TMR procedures</td>
    </tr>
    <tr>
      <td>If PMC is     approved,  it  <font color="blue">could erode</font> the potential TMR <font color="blue">market which would</font> have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Rapid <font color="blue">technological</font> changes in our industry could make our <font color="blue">products obsolete</font>       Our industry is characterized by rapid <font color="blue">technological</font> change and intense     <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>New <font color="blue">technologies</font> and products and <font color="blue">new industry standards will</font>     develop at a rapid pace, which could make our current and future planned     <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>The advent of new devices and procedures and advances in     new drugs and <font color="blue">genetic engineering</font> are especially concerning <font color="blue">competitive</font>     threats</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success will depend upon</font> our ability to develop and     introduce  <font color="blue">product enhancements</font> to address the needs of our customers</td>
    </tr>
    <tr>
      <td>Material delays in introducing <font color="blue">product enhancements</font> may cause customers to     <font color="blue">forego purchases</font> of our products and purchase those of our <font color="blue">competitor</font>s</td>
    </tr>
    <tr>
      <td>Many potential <font color="blue">competitor</font>s have <font color="blue">substantially greater financial resources</font>     and are in a <font color="blue">better financial position</font> to <font color="blue">exploit marketing</font> and research and     <font color="blue">development</font> opportunities</td>
    </tr>
    <tr>
      <td>In addition, we are aware that other companies     are  developing  or already have developed <font color="blue">proprietary systems</font> for the     treatment of cardiac <font color="blue">arrhythmias</font>, and <font color="blue">specifically</font> AF, that may be safer,     <font color="blue">clinically</font> more <font color="blue">effective</font>, easier and more cost <font color="blue">effective</font> to use and, in the     case  of  <font color="blue">percutaneous</font>  devices,  <font color="blue">less invasive</font> than the system we are     developing</td>
    </tr>
    <tr>
      <td>We must receive and maintain <font color="blue"><font color="blue">government</font> <font color="blue">clearances</font></font> or approvals in order to     market our products       Our products and our manufacturing <font color="blue">activities</font> are subject to extensive,     rigorous  and changing federal and state regulation <font color="blue">in the US </font>and to     similar  <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> in other <font color="blue">major <font color="blue">international</font> markets</font>,     including the <font color="blue"><font color="blue">European Union </font>and Japan</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> and <font color="blue">regulatory</font>     <font color="blue">requirements</font> are broad in scope and govern, among other things:       ·       <font color="blue">product design</font> and <font color="blue">development</font>;       ·       <font color="blue">product testing</font>;       ·       <font color="blue">product labeling</font>;       ·       <font color="blue">product storage</font>;       ·       <font color="blue">premarket clearance</font> and approval;       ·       <font color="blue">advertising</font> and promotion; and       ·       <font color="blue">product sales</font> and <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>15     ______________________________________________________________________       Furthermore,  <font color="blue">regulatory</font>  <font color="blue">authorities</font>  subject a <font color="blue">marketed product</font>, its     <font color="blue">manufacturer</font>  and the <font color="blue">manufacturing facilities</font> to <font color="blue">continual review</font> and     <font color="blue">periodic inspections</font></td>
    </tr>
    <tr>
      <td>We are subject to ongoing FDA <font color="blue">requirements</font>, including     required  <font color="blue">submissions</font>  of safety and other post-market information and     reports,  <font color="blue">registration</font>  <font color="blue">requirements</font>, <font color="blue">Quality Systems </font><font color="blue">regulations</font>, and     recordkeeping <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>The FDA’s <font color="blue">Quality Systems </font><font color="blue">regulations</font> include     <font color="blue">requirements</font> relating to <font color="blue">quality control</font> and quality assurance, as well as     the <font color="blue">corresponding maintenance</font> of records and <font color="blue">documentation</font></td>
    </tr>
    <tr>
      <td>Edwards, our     <font color="blue">distributor</font>,  depending  on its <font color="blue">activities</font>, is also subject to certain     <font color="blue">requirements</font>  under  the  Federal Food, Drug, and Cosmetic Act and the     <font color="blue">regulations</font>  promulgated  thereunder,  and state laws and <font color="blue">registration</font>     <font color="blue">requirements</font> covering the <font color="blue">distribution</font> of our products</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>agencies     may change existing <font color="blue">requirements</font> or adopt new <font color="blue">requirements</font> or policies that     could   affect  our  <font color="blue">regulatory</font>  <font color="blue">responsibilities</font>  or  the  <font color="blue">regulatory</font>     <font color="blue">responsibilities</font> of a <font color="blue">distributor</font> like Edwards</td>
    </tr>
    <tr>
      <td>We may be slow to adapt or     may not be able to adapt to these changes or new <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Later  <font color="blue">discovery</font>  of  <font color="blue">previously</font>  unknown  <font color="blue">problems with</font> our products,     <font color="blue">manufacturing processes</font>, or our failure to <font color="blue">comply with</font> applicable <font color="blue">regulatory</font>     <font color="blue">requirements</font>  may  result  in <font color="blue"><font color="blue">enforcement actions</font> by</font> the FDA and other     <font color="blue">international</font> <font color="blue">regulatory</font> <font color="blue">authorities</font>, including, but not limited to:       ·       <font color="blue">warning letters</font>;       ·       patient or <font color="blue">physician notification</font>;       ·       <font color="blue">restrictions on</font> our products or <font color="blue">manufacturing processes</font>;       ·       voluntary or <font color="blue">mandatory recalls</font>;       ·       <font color="blue">product seizures</font>;       ·       refusal to <font color="blue">approve pending <font color="blue">applications</font></font> or <font color="blue">supplements</font> to approved     <font color="blue">applications</font> that we submit;       ·       refusal to permit the import or export of our products;       ·       fines;       ·       <font color="blue">injunctions</font>;       ·       suspension or withdrawal of <font color="blue">marketing approvals</font> or <font color="blue">clearances</font>; and       ·       civil and <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td>Should any of these <font color="blue">enforcement actions</font> occur, our business, financial     condition  and results of <font color="blue">operations</font> could be <font color="blue">materially</font> and <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>To  date,  we have received the following <font color="blue">regulatory</font> approvals for our     products:       <font color="blue">Heart Laser Systems</font>       <font color="blue">United States</font>—We received FDA approval to market the HL1 Heart Laser System     in August 1998 and the HL2 Heart Laser System in January 2001</td>
    </tr>
    <tr>
      <td>However,     although we have received FDA approval, the FDA:       ·       has restricted the use of the <font color="blue">Heart Laser Systems</font> by not <font color="blue">allowing us</font>     to market these products to <font color="blue">treat patients whose condition</font> is amenable to     <font color="blue">conventional</font>  <font color="blue">treatments</font>,  such  as heart bypass surgery, stenting and     <font color="blue">angioplasty</font>; and       ·       could impose <font color="blue">additional</font> restrictions or reverse its ruling and     <font color="blue">prohibit use</font> of the <font color="blue">Heart Laser Systems</font> at any time</td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________       Europe—We received the CE Mark from the <font color="blue">European Union </font>for the HL1 and HL2     in March 1995 and <font color="blue">February </font>2001, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>However:       ·       our current ISO certification (13485-1996) that <font color="blue">enables us</font> to apply     the CE mark and ship our <font color="blue">products into</font> the EU will expire on July 31, 2006</td>
    </tr>
    <tr>
      <td>We <font color="blue">must conform</font> our <font color="blue">quality system</font> to a new ISO standard (13485-2003),     undergo an audit and be <font color="blue">certified by</font> our <font color="blue">registrar prior</font> to July 31, 2006,     in order to be able to continue to ship our <font color="blue">products into</font> the EU We are     currently  in the process of <font color="blue">implementing</font> the <font color="blue">necessary</font> changes to our     <font color="blue">quality system</font> in order to conform to the new ISO standard, however, we     cannot  provide  any  assurance  that  we <font color="blue">will timely meet</font> or maintain     conformance to the <font color="blue">requirements</font> of the new standard before July 31, 2006 or     in the future;       ·       the <font color="blue">European Union </font>could impose <font color="blue">additional</font> restrictions or reverse     its ruling and <font color="blue">prohibit use</font> of the <font color="blue">Heart Laser Systems</font> at any time; and       ·       France has prohibited, and other <font color="blue">European Union </font><font color="blue">countries could</font>     prohibit or restrict, use of the <font color="blue">Heart Laser Systems</font></td>
    </tr>
    <tr>
      <td>Japan—We <font color="blue">cannot market</font> our product in Japan until we receive <font color="blue">government</font>     approval</td>
    </tr>
    <tr>
      <td>Prior  to  marketing the <font color="blue">Heart Laser Systems</font> in Japan, we must receive     <font color="blue">approval from</font> the Japanese <font color="blue">government</font></td>
    </tr>
    <tr>
      <td>Although the results of this study have been submitted to the     Japanese <font color="blue">government</font>, we do not know whether the <font color="blue">clinical study will</font> be     sufficient or when, if ever, we will receive approval to sell the HL1 in     Japan</td>
    </tr>
    <tr>
      <td>In addition, it is unclear what impact the introduction of the HL2     into the US and other <font color="blue"><font color="blue">international</font> markets will</font> have on our ability to     market the HL1 in Japan</td>
    </tr>
    <tr>
      <td>Optiwave 980 System       <font color="blue">United States</font>—The FDA has <font color="blue">given clearance</font> to <font color="blue">the Optiwave </font>980 System through     the 510(k) premarket notification process with indications for use as a     surgical  instrument for <font color="blue">coagulation</font> of <font color="blue">soft tissue</font>, including cardiac     tissue, in <font color="blue">conjunction with</font> or <font color="blue">without endoscopic equipment</font> in the contact     or non-contact mode in open or closed <font color="blue">surgical procedures</font></td>
    </tr>
    <tr>
      <td>Although <font color="blue">the Optiwave </font>980 System has received clearance from the FDA only     for the indications of use stated above, physicians, under the practice of     medicine exception, may use the device in any manner they choose in treating     an individual patient, including using the device to <font color="blue">treat patients with</font> AF     However, neither we nor Edwards have conducted any <font color="blue">clinical trial</font>s designed     to obtain data to submit to the FDA for the purpose of obtaining a specific     indication for use of <font color="blue">the Optiwave </font>980 System that <font color="blue">would allow us</font> or <font color="blue">Edwards  </font>   to make claims or otherwise market this device for the treatment of AF We     are aware of several other companies that have announced their plans to     conduct <font color="blue">clinical trial</font>s in support of a labeling claim that <font color="blue">would allow them</font>     to market their devices for the treatment of AF if clearance is obtained     from the FDA       In the event these other <font color="blue">competitor</font>s are successful in obtaining specific     indications of use for their devices in the treatment of AF, <font color="blue">the Optiwave </font>    980 System may be at a <font color="blue">competitive</font> marketing disadvantage until such time,     if ever, that Edwards conducts a <font color="blue">clinical trial</font>, submits sufficient data to     the  FDA  by means of a new 510(k) and obtains clearance to market the     Optiwave 980 System for the treatment of AF We <font color="blue">cannot provide</font> any assurance     that Edwards will ever conduct such a <font color="blue">clinical trial</font> or, if they do, that     the data they obtain and submit to the FDA will be sufficient for the FDA to     expand the current indications of use and provide clearance for <font color="blue">the Optiwave </font>    980 System to be marketed for the treatment of AF Also, we <font color="blue">cannot assure</font>     you that even if <font color="blue">such clearance</font> is obtained, that it will be obtained in a     timely  enough  fashion  for our products to remain <font color="blue">competitive</font> in the     marketplace</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________       Europe—The Optiwave 980 System cannot be marketed in the EU until such time     as it receives CE Mark approval</td>
    </tr>
    <tr>
      <td>Edwards needs to complete and submit the     relevant technical <font color="blue">documentation</font> to the <font color="blue">appropriate certifying</font> body in order     to be able to apply the CE Mark to the product</td>
    </tr>
    <tr>
      <td>If approval to apply the CE     Mark is granted, <font color="blue">the Optiwave </font>980 System will then be able to be <font color="blue">distributed</font>     in the EU       Changes  in third party <font color="blue">reimbursement</font> for either TMR or cardiac tissue     ablation procedures could <font color="blue">materially</font> affect future demand for our products       Demand  for  medical  devices is often affected by whether third party     <font color="blue">reimbursement</font> is available for the devices and related procedures</td>
    </tr>
    <tr>
      <td>Currently     Medicare coverage is provided for TMR when it is performed as a <font color="blue">sole therapy</font>     treatment</td>
    </tr>
    <tr>
      <td>In addition, when two or more <font color="blue">medical procedures</font> are performed in     <font color="blue"><font color="blue">combination with</font> each</font> other, Medicare <font color="blue">rules generally allow hospitals</font> to     bill for whichever of the <font color="blue">two procedures</font> carries the higher <font color="blue">reimbursement</font>     amount</td>
    </tr>
    <tr>
      <td>Therefore, in situations where <font color="blue">sole therapy</font> TMR <font color="blue">reimbursement</font> rates     exceed  that provided for <font color="blue">bypass surgery alone</font>, if hospitals perform a     <font color="blue">combination procedure</font> where <font color="blue">both bypass surgery</font> and <font color="blue">adjunctive</font> TMR are     performed on a patient, the hospital is able to bill for the higher TMR     procedure <font color="blue">reimbursement</font> payment</td>
    </tr>
    <tr>
      <td>In these instances, the <font color="blue">doctor also</font> can     bill an <font color="blue">additional</font> amount for performing <font color="blue">multiple procedures</font></td>
    </tr>
    <tr>
      <td>Certain <font color="blue">private <font color="blue">insurance companies</font></font> and health <font color="blue">maintenance organizations</font>     also currently provide <font color="blue">reimbursement</font> for TMR procedures performed with our     products and physician <font color="blue">reimbursement</font> codes have <font color="blue">been established</font> for both     <font color="blue">surgical procedures</font>; however, we have limited data as to the breadth of this     coverage <font color="blue">for the TMR </font>procedure by <font color="blue">private <font color="blue">insurance companies</font></font> and health     <font color="blue">maintenance organizations</font></td>
    </tr>
    <tr>
      <td>Cardiac tissue ablation procedures, such as those that are expected to be     performed using <font color="blue">the Optiwave </font>980 System, are <font color="blue">also currently reimbursed by</font>     Medicare when performed as a <font color="blue">sole therapy</font></td>
    </tr>
    <tr>
      <td>In instances where a surgeon     might  perform a <font color="blue">cardiac tissue ablation procedure</font> in <font color="blue">combination with</font>     another heart related procedure, such as a <font color="blue">valve replacement</font> or repair, we     believe the other <font color="blue">procedure will normally</font> carry a higher <font color="blue">reimbursement</font> and,     therefore, will be the procedure that the <font color="blue">hospital bills</font> to Medicare</td>
    </tr>
    <tr>
      <td>No assurance can be given, however, that these <font color="blue">payers will continue</font> to     <font color="blue">reimburse healthcare providers</font> who perform TMR or cardiac tissue ablation     <font color="blue">procedures using</font> our products now or in the future</td>
    </tr>
    <tr>
      <td>Further, no assurance     can be given that <font color="blue">additional</font> payers will <font color="blue">reimburse healthcare providers</font> who     perform TMR or cardiac tissue ablation <font color="blue">procedures using</font> our products or that     <font color="blue">reimbursement</font>, if provided, will be timely or adequate</td>
    </tr>
    <tr>
      <td>In addition, the     market for our <font color="blue">products could</font> be <font color="blue"><font color="blue">adversely</font> affected</font> by future legislation to     reform the nation’s healthcare system or by changes in <font color="blue">industry practices</font>     regarding <font color="blue">reimbursement</font> policies and procedures</td>
    </tr>
    <tr>
      <td>Should third party insurance <font color="blue">reimbursement</font> for either TMR or cardiac tissue     ablation procedures be reduced or eliminated in the future, our business,     financial  condition and results of <font color="blue">operations</font> would be <font color="blue">materially</font> and     <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td><font color="blue">Asserting </font>and defending <font color="blue">intellectual</font> property rights may impact our results     of <font color="blue">operations</font>       In our industry, <font color="blue">competitor</font>s often assert <font color="blue">intellectual</font> property infringement     claims <font color="blue">against one</font> another</td>
    </tr>
    <tr>
      <td>The success of our business <font color="blue">depends on</font> our     ability to <font color="blue">successfully defend</font> our <font color="blue">intellectual</font> property</td>
    </tr>
    <tr>
      <td>Future <font color="blue">litigation</font>     may  have  a material <font color="blue">impact on</font> our <font color="blue">financial condition</font> even if we are     successful in marketing our products</td>
    </tr>
    <tr>
      <td>We may not be successful in defending     or asserting our <font color="blue">intellectual</font> property rights</td>
    </tr>
    <tr>
      <td>An  <font color="blue">adverse outcome</font> in any <font color="blue">litigation</font> or <font color="blue">interference proceeding could</font>     subject us to <font color="blue">significant</font> liabilities to <font color="blue">third parties</font> and require us to     <font color="blue">cease using</font> the <font color="blue">technology</font> that is at issue or to license the <font color="blue">technology</font>     from <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>In addition, a finding that any of our <font color="blue">intellectual</font>     property  is  invalid  could  allow our <font color="blue">competitor</font>s to more easily and     cost-<font color="blue">effective</font>ly compete with us</td>
    </tr>
    <tr>
      <td>Thus, an unfavorable outcome       18     ______________________________________________________________________       in any patent <font color="blue">litigation</font> or <font color="blue">interference proceeding could</font> have a material     adverse  effect  on  our  business,  <font color="blue">financial condition</font> or results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The cost to us of any patent <font color="blue">litigation</font> or <font color="blue">interference proceeding could</font> be     substantial</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties </font>resulting from the <font color="blue">initiation</font> and <font color="blue">continuation</font> of     patent <font color="blue">litigation</font> or <font color="blue">interference proceedings could</font> have a material adverse     effect on our ability to compete in the marketplace</td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation</font> and     interference proceedings may also absorb <font color="blue">significant</font> <font color="blue">management</font> time</td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue">product <font color="blue">liability</font></font> lawsuits; our <font color="blue">insurance may</font> not be     sufficient to <font color="blue">cover damages</font>       We  may be subject to <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>Such claims may absorb     <font color="blue">significant</font>  <font color="blue">management</font>  time and <font color="blue">could degrade</font> our reputation and the     <font color="blue">marketability</font> of our products</td>
    </tr>
    <tr>
      <td>If <font color="blue">product <font color="blue">liability</font></font> claims are made with     respect to our products, we may need to recall the <font color="blue">implicated product which</font>     could have a material adverse effect on our business, <font color="blue">financial condition</font>     and  results  of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, although we maintain product     <font color="blue"><font color="blue">liability</font> insurance</font>, we cannot be sure that our <font color="blue">insurance will</font> be adequate     to cover potential <font color="blue">product <font color="blue">liability</font></font> lawsuits</td>
    </tr>
    <tr>
      <td>Our insurance is expensive     and in the <font color="blue">future may</font> not be <font color="blue">available on</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>If a     successful <font color="blue">product <font color="blue">liability</font></font> claim or series of claims exceeds our insurance     coverage, it could have a material adverse effect on our business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are subject to risks associated with <font color="blue">international</font> <font color="blue">operations</font>       A portion of our <font color="blue">product sales</font> are generated from <font color="blue">operations</font> outside of the     US Establishing, maintaining and <font color="blue">expanding <font color="blue">international</font> sales</font> can be     expensive</td>
    </tr>
    <tr>
      <td>Managing and overseeing foreign <font color="blue">operations</font> are <font color="blue">difficult</font> and     products may not receive market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>Risks of doing business outside     the US include, but are not limited to, the following: agreements may be     <font color="blue">difficult</font> to enforce and receivables <font color="blue">difficult</font> to <font color="blue">collect through</font> a foreign     country’s legal system; foreign customers may have <font color="blue">longer payment cycles</font>;     <font color="blue">foreign countries may</font> impose <font color="blue">additional</font> withholding taxes or otherwise tax     our foreign income, impose tariffs or adopt other <font color="blue">restrictions on</font> foreign     trade; US <font color="blue">export licenses may</font> be <font color="blue">difficult</font> to obtain; and the protection     of <font color="blue">intellectual</font> property rights in <font color="blue">foreign countries may</font> be more <font color="blue">difficult</font>     to enforce</td>
    </tr>
    <tr>
      <td>There can be no assurance that our <font color="blue">international</font> business will     grow  or that any of the <font color="blue">foregoing risks will</font> not result in a material     adverse effect on our business or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font>     sales have declined since 2003</td>
    </tr>
    <tr>
      <td>We  will  soon  have  to <font color="blue"><font color="blue">comply with</font> internal controls <font color="blue">evaluation</font>s</font> and     attestation <font color="blue">requirements</font>       <font color="blue">Pursuant  </font>to Section 404 of the Sarbanes-Oxley Act of 2002, we will be     required, beginning with our year ending <font color="blue">December </font>31, 2007, to perform an     <font color="blue">evaluation</font> of our <font color="blue">internal controls over financial</font> reporting and have our     in<font color="blue">dependent</font> registered public accounting firm attest to such <font color="blue">evaluation</font></td>
    </tr>
    <tr>
      <td>We     are developing a program to perform this <font color="blue">evaluation</font> in order to <font color="blue">comply with</font>     these <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with these <font color="blue">requirements</font> is expected to be     expensive and time-consuming</td>
    </tr>
    <tr>
      <td>If we fail to timely complete this <font color="blue">evaluation</font>,     or if our in<font color="blue">dependent</font> registered public accounting firm cannot timely attest     to our <font color="blue">evaluation</font>, we could be subject to <font color="blue">regulatory</font> action and public     confidence in us could be <font color="blue"><font color="blue">adversely</font> affected</font> and our <font color="blue">stock price could</font>     decline</td>
    </tr>
    <tr>
      <td>In addition, any failure to implement required new or improved     controls, or <font color="blue">difficult</font>ies encountered in their <font color="blue">implementation</font>, could harm     our operating results or cause us to fail to meet our reporting <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we are incorporated in Canada, you may not be able to enforce     <font color="blue">judgments <font color="blue">against us</font></font> and our <font color="blue">Canadian </font><font color="blue">directors</font>       Under <font color="blue">Canadian </font>law, you may not be able to enforce a <font color="blue">judgment issued by</font>     courts <font color="blue">in the US </font><font color="blue">against us</font> or our <font color="blue">Canadian </font><font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>The status of the     law in Canada is <font color="blue">unclear as</font> to whether a US citizen can       19     ______________________________________________________________________       enforce  a <font color="blue">judgment from</font> a US court in Canada for violations <font color="blue">of US     </font><font color="blue">securities laws</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">separate suit may</font> need to be <font color="blue">brought directly</font> in Canada</td>
    </tr>
    <tr>
      <td>Our stock price has <font color="blue">historically fluctuated</font> and <font color="blue">may continue</font> to fluctuate     <font color="blue"><font color="blue">significant</font>ly</font> in the <font color="blue">future which may</font> result in losses for our investors       Our  stock price has been and <font color="blue">may continue</font> to be volatile</td>
    </tr>
    <tr>
      <td>Some of the     factors that can affect our stock price are:       ·        the  <font color="blue">announcement</font>  of new products, services or <font color="blue">technological</font>     innovations by us or our <font color="blue">competitor</font>s;       ·       actual or anticipated <font color="blue">quarterly increases</font> or <font color="blue">decreases</font> in revenue,     gross  margin  or earnings, and changes in our business, <font color="blue">operations</font> or     prospects;       ·       <font color="blue">speculation</font> or actual news <font color="blue">announcement</font>s in the media or industry     <font color="blue">trade journals about</font> our company, our products, the TMR or cardiac ablation     procedures or changes in <font color="blue">reimbursement</font> policies by Medicare and/or private     <font color="blue">insurance companies</font>;       ·       <font color="blue">announcement</font>s relating to <font color="blue">strategic relationships</font> or mergers;       ·       <font color="blue">conditions</font> or trends in the medical device industry;       ·       changes in the <font color="blue">economic performance</font> or <font color="blue">market valuations</font> of other     medical device companies; and       ·       general market <font color="blue">conditions</font> or domestic or <font color="blue">international</font> macroeconomic     and <font color="blue">geopolitical factors unrelated</font> to our performance</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our stock may fall if <font color="blue">shareholders</font> sell their stock       Certain current <font color="blue">shareholders</font> hold large amounts of our stock, which they     <font color="blue">could sell</font> in the <font color="blue">public market from</font> time to time</td>
    </tr>
    <tr>
      <td>Sales of a substantial     number of shares of our <font color="blue"><font color="blue">common stock</font> within</font> a short period of time could     cause our stock price to fall</td>
    </tr>
    <tr>
      <td>In addition, the sale of these <font color="blue">shares could</font>     impair our ability to <font color="blue">raise capital through</font> the sale of <font color="blue">additional</font> stock</td>
    </tr>
    <tr>
      <td>We have <font color="blue">no intention</font> to <font color="blue">pay dividends</font>       We have never paid any <font color="blue">cash dividends on</font> our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We currently     intend to retain all <font color="blue">future earnings</font>, if any, for use in our business and do     not expect to pay any dividends in the <font color="blue">foreseeable future</font></td>
    </tr>
  </tbody>
</table>